ECSP21080618A - Methods and Compositions for Editing RNAs - Google Patents

Methods and Compositions for Editing RNAs

Info

Publication number
ECSP21080618A
ECSP21080618A ECSENADI202180618A ECDI202180618A ECSP21080618A EC SP21080618 A ECSP21080618 A EC SP21080618A EC SENADI202180618 A ECSENADI202180618 A EC SENADI202180618A EC DI202180618 A ECDI202180618 A EC DI202180618A EC SP21080618 A ECSP21080618 A EC SP21080618A
Authority
EC
Ecuador
Prior art keywords
editing
methods
compositions
rna
anns
Prior art date
Application number
ECSENADI202180618A
Other languages
English (en)
Inventor
Wensheng Wei
Pengfei Yuan
Chunhui Wang
Gangbin Tang
Zhongzheng Cao
Zongyi Yi
Shiyou Zhu
Zhuo Zhou
Nengyin Liu
Zexuan Yi
Yanxia Zhao
Liang Qu
Original Assignee
Univ Beijing
Edigene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Beijing, Edigene Inc filed Critical Univ Beijing
Publication of ECSP21080618A publication Critical patent/ECSP21080618A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

La presente solicitud proporciona métodos para editar ARN mediante la introducción de un ARN de reclutamiento de desaminasas en una célula hospedera para la desaminación de una adenosina en un ARN objetivo; la presente solicitud proporciona además ARN de reclutamiento de desaminasas usados en los métodos de edición de ARN y composiciones que los comprenden.
ECSENADI202180618A 2019-04-15 2021-11-15 Methods and Compositions for Editing RNAs ECSP21080618A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019082713 2019-04-15
CN2019129952 2019-12-30
PCT/CN2020/084922 WO2020211780A1 (en) 2019-04-15 2020-04-15 Methods and compositions for editing rnas

Publications (1)

Publication Number Publication Date
ECSP21080618A true ECSP21080618A (es) 2021-12-30

Family

ID=72837012

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202180618A ECSP21080618A (es) 2019-04-15 2021-11-15 Methods and Compositions for Editing RNAs

Country Status (18)

Country Link
US (2) US20220307020A1 (es)
EP (1) EP3956449A4 (es)
JP (1) JP2022526455A (es)
KR (1) KR20220004674A (es)
CN (1) CN113939591A (es)
AU (1) AU2020259548B2 (es)
BR (1) BR112021020608A8 (es)
CA (1) CA3136735A1 (es)
CL (1) CL2021002695A1 (es)
CO (1) CO2021015214A2 (es)
CR (1) CR20210572A (es)
EC (1) ECSP21080618A (es)
IL (1) IL287248A (es)
MX (1) MX2021012645A (es)
PE (1) PE20212214A1 (es)
SG (1) SG11202111401RA (es)
TW (1) TW202043249A (es)
WO (1) WO2020211780A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017220751A1 (en) 2016-06-22 2017-12-28 Proqr Therapeutics Ii B.V. Single-stranded rna-editing oligonucleotides
US20220307020A1 (en) 2019-04-15 2022-09-29 Edigene Inc. Methods and compositions for editing rnas
EP3997229A4 (en) 2019-07-12 2024-07-03 Univ Beijing TARGETED RNA EDITING BY HARNESSING ENDOGENOUS ADAR USING MODIFIED RNA
CN115038789A (zh) 2019-12-02 2022-09-09 塑造治疗公司 治疗性编辑
AU2020418228A1 (en) * 2019-12-30 2022-08-18 Edigene Therapeutics (Beijing) Inc. Leaper technology based method for treating MPS IH and composition
IL294260A (en) * 2019-12-30 2022-08-01 Edigene Therapeutics Beijing Inc A method and preparation for the treatment of Asher syndrome
EP4137161A4 (en) * 2020-04-15 2023-10-11 EdiGene Therapeutics (Beijing) Inc. METHOD AND MEDICATION FOR THE TREATMENT OF HURLER SYNDROME
CN113528582B (zh) * 2020-04-15 2022-05-17 博雅辑因（北京）生物科技有限公司 基于leaper技术靶向编辑rna的方法和药物
JP2023529316A (ja) * 2020-05-26 2023-07-10 シェイプ セラピューティクス インコーポレイテッド ゲノム編集のための組成物及び方法
CN117015605A (zh) * 2021-01-12 2023-11-07 北京大学 使用工程化rna通过利用内源性adar进行靶向rna编辑
US20230194709A9 (en) * 2021-06-29 2023-06-22 Seagate Technology Llc Range information detection using coherent pulse sets with selected waveform characteristics
TW202321451A (zh) * 2021-08-18 2023-06-01 北京大學 工程化的 adar 招募 rnas 及其使用方法
WO2023143539A1 (en) * 2022-01-28 2023-08-03 Edigene Therapeutics (Beijing) Inc. Engineered adar-recruiting rnas and methods of use thereof
WO2023152371A1 (en) 2022-02-14 2023-08-17 Proqr Therapeutics Ii B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
WO2024013360A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Chemically modified oligonucleotides for adar-mediated rna editing
WO2024013361A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Oligonucleotides for adar-mediated rna editing and use thereof
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
WO2024110565A1 (en) 2022-11-24 2024-05-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
WO2024121373A1 (en) 2022-12-09 2024-06-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
WO2024206175A1 (en) 2023-03-24 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
WO2024200472A1 (en) 2023-03-27 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK187280A (da) 1980-04-30 1981-10-31 Novo Industri As Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode
US5773244A (en) 1993-05-19 1998-06-30 Regents Of The University Of California Methods of making circular RNA
RU2597972C2 (ru) 2010-10-22 2016-09-20 Курна Инк. Лечение заболеваний, связанных с геном альфа-l-идуронидазы (idua), путем ингибирования природного антисмыслового транскрипта гена idua
US9650627B1 (en) 2012-07-19 2017-05-16 University Of Puerto Rico Site-directed RNA editing
WO2015134812A1 (en) 2014-03-05 2015-09-11 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
EP4372091A3 (en) 2014-12-12 2024-07-31 Tod M. Woolf Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
US10676737B2 (en) 2014-12-17 2020-06-09 Proqr Therapeutics Ii B.V. Targeted RNA editing
EP3323890A4 (en) 2015-07-14 2019-01-30 Fukuoka University METHOD FOR INDUCING SITE SPECIFIC RNA MUTATIONS, TARGET EDITION GUIDING RNA-GUIDE USED IN THE METHOD, AND TARGET EDITING GUID-RNA TARGET RNA COMPLEX
DE102015012522B3 (de) * 2015-09-26 2016-06-02 Eberhard Karls Universität Tübingen Verfahren und Substanzen zur gerichteten RNA-Editierung
DK3448999T3 (da) 2016-04-25 2020-06-08 Proqr Therapeutics Ii Bv Oligonukleotider til behandling af øjensygdom
WO2017220751A1 (en) * 2016-06-22 2017-12-28 Proqr Therapeutics Ii B.V. Single-stranded rna-editing oligonucleotides
WO2018041873A1 (en) 2016-09-01 2018-03-08 F. Hoffmann-La Roche Ag Process for the preparation of (6s)-6-isopropyl-10-methoxy-9-(3-methoxypropoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid
CA3035293A1 (en) * 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
GB201616202D0 (en) 2016-09-23 2016-11-09 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of eye deisease
EP3571300A1 (en) 2017-01-19 2019-11-27 ProQR Therapeutics II B.V. Oligonucleotide complexes for use in rna editing
CN118416088A (zh) 2017-03-03 2024-08-02 加利福尼亚大学董事会 经由抑制性tRNAs和脱氨酶对突变进行RNA靶向
CN110869498A (zh) 2017-05-10 2020-03-06 加利福尼亚大学董事会 经由核递送crispr/cas9导向编辑细胞rna
US20200248169A1 (en) 2017-06-26 2020-08-06 The Broad Institute, Inc. Crispr/cas-cytidine deaminase based compositions, systems, and methods for targeted nucleic acid editing
CA3073848A1 (en) 2017-09-21 2019-03-28 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
EP3688159A4 (en) 2017-09-26 2021-10-20 The Board of Trustees of the University of Illinois CRISPR / CAS SYSTEM AND PROCESS FOR GENOME EDITING AND TRANSCRIPT MODULATION
CN111727247A (zh) 2017-10-04 2020-09-29 博德研究所 用于靶向核酸编辑的系统、方法和组合物
CA3084632A1 (en) 2017-12-21 2019-06-27 Crispr Therapeutics Ag Materials and methods for treatment of usher syndrome type 2a
EP3752611A1 (en) 2018-02-14 2020-12-23 ProQR Therapeutics II B.V. Antisense oligonucleotides for rna editing
EP3768303A4 (en) 2018-03-23 2021-12-29 Massachusetts Eye and Ear Infirmary Crispr/cas9-mediated exon-skipping approach for ush2a-associated usher syndrome
WO2020001793A1 (en) * 2018-06-29 2020-01-02 Eberhard-Karls-Universität Tübingen Artificial nucleic acids for rna editing
US20220010333A1 (en) 2018-09-06 2022-01-13 The Regents Of The University Of California Rna and dna base editing via engineered adar recruitment
MX2021004187A (es) 2018-10-12 2021-09-08 Edigene Therapeutics Beijing Inc Métodos y composiciones para editar ácidos ribonucleicos.
CN113646434B (zh) 2018-12-20 2023-05-30 北京大学 使用加标签的向导rna构建体进行高效基因筛选的组合物和方法
EP3924484A4 (en) 2019-02-13 2024-07-17 Beam Therapeutics Inc METHODS OF EDITING A DISEASE-ASSOCIATED GENE USING ADENOSINE DEAMINASE BASE EDITORS, INCLUDING FOR TREATING A GENETIC DISEASE
CN109943586B (zh) 2019-03-15 2021-02-26 上海交通大学 一种植物circRNA过表达载体及其构建方法
US20220307020A1 (en) 2019-04-15 2022-09-29 Edigene Inc. Methods and compositions for editing rnas
EP3964579A4 (en) 2019-04-30 2023-07-26 EdiGene (GuangZhou) Inc. METHOD OF PREDICTING THE EFFECTIVENESS OF THE TREATMENT OF HEMOGLOBINOPATHY
EP3997229A4 (en) 2019-07-12 2024-07-03 Univ Beijing TARGETED RNA EDITING BY HARNESSING ENDOGENOUS ADAR USING MODIFIED RNA
CA3150230A1 (en) 2019-09-04 2021-03-11 Pengfei YUAN METHOD FOR EVALUATING GENE EDITING THERAPY BASED ON OFF-TARGET EVALUATION
JP2023507486A (ja) 2019-12-16 2023-02-22 ▲広▼州▲輯▼因医▲療▼科技有限公司 造血幹細胞を増幅するための小分子化合物、及びそれらの組み合わせ
IL294260A (en) 2019-12-30 2022-08-01 Edigene Therapeutics Beijing Inc A method and preparation for the treatment of Asher syndrome
AU2020418228A1 (en) 2019-12-30 2022-08-18 Edigene Therapeutics (Beijing) Inc. Leaper technology based method for treating MPS IH and composition
AU2020417930A1 (en) 2019-12-31 2022-08-18 Edigene Therapeutics (Beijing) Inc. New method for targeted editing of RNA
DE102020126779A1 (de) 2020-10-13 2022-04-14 Fritsch Bakery Technologies GmbH & Co. KG Teigverarbeitungsmaschine zum Bearbeiten von Produkten
CN117015605A (zh) 2021-01-12 2023-11-07 北京大学 使用工程化rna通过利用内源性adar进行靶向rna编辑

Also Published As

Publication number Publication date
SG11202111401RA (en) 2021-11-29
MX2021012645A (es) 2021-11-12
PE20212214A1 (es) 2021-11-19
BR112021020608A2 (pt) 2022-02-22
CN113939591A (zh) 2022-01-14
EP3956449A4 (en) 2023-03-29
TW202043249A (zh) 2020-12-01
CO2021015214A2 (es) 2022-02-07
IL287248A (en) 2021-12-01
EP3956449A1 (en) 2022-02-23
WO2020211780A1 (en) 2020-10-22
AU2020259548B2 (en) 2023-10-12
US11702658B2 (en) 2023-07-18
US20220098587A1 (en) 2022-03-31
CA3136735A1 (en) 2020-10-22
CR20210572A (es) 2022-04-07
AU2020259548A1 (en) 2021-12-09
KR20220004674A (ko) 2022-01-11
US20220307020A1 (en) 2022-09-29
BR112021020608A8 (pt) 2023-03-21
CL2021002695A1 (es) 2022-07-01
JP2022526455A (ja) 2022-05-24

Similar Documents

Publication Publication Date Title
ECSP21080618A (es) Methods and Compositions for Editing RNAs
ECSP21033637A (es) Methods and Compositions for Editing RNAs
CO2022001359A2 (es) Edición de ácido ribonucleico (arn) dirigido aprovechando la adenosina desaminasa que actúa sobre ácido ribonucleico endógeno (adar) utilizando ácidos ribonucleicos (arn) modificados genéticamente
CO2018004763A2 (es) Edición genómica multiplexada
BR102016018569A2 (pt) sistemas e métodos de retentor para eletrodo de soldagem com bastão
BR112020024863A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
BR112018076190A2 (pt) ortólogos e sistemas crispr tipo vi
BR112018069417A2 (pt) método para fornecer rna fita simples e ssrna
CO2017009083A2 (es) Arni dirigido a la proteína hungtingtina, partículas víricas que lo contienen y métodos para reducir la toxicicidad del arni
CL2017002514A1 (es) Anticuerpos anti-c1s humanizados y métodos para usarlos.
CO2020003882A2 (es) Anticuerpo multiespecifico
AR108611A1 (es) Anticuerpos anti-cd40 y sus usos
BR112015030946A8 (pt) composição compreendendo uma célula ß pancreática não-nativa, método de diferenciação de células progenitoras em células ß pancreáticas in vitro e uso de uma célula ß pancreática não-nativa
BR112022002695A2 (pt) Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso
BR112017017279A2 (pt) métodos para introduzir um gene inibidor de pólen, para introduzir dois genes inibidores de pólen, para introduzir dois genes marcadores coloridos e de introgressão acelerada de traço e planta
CL2021001034A1 (es) Métodos y composiciones para terapia con células oculares
BR112022017196A2 (pt) Recombinação genômica guiada por rna na escala de kilobase
CR20240112A (es) Compuestos y métodos para modular splicing
AR110871A1 (es) Proteínas de fusión de factor ix y métodos de fabricación y uso de las mismas
CO2021006679A2 (es) Métodos para formar poliplejos
EA202191004A1 (ru) Способы и композиции для редактирования рнк
BR112021019300A2 (pt) Composto, composição farmacêutica, e método para tratar câncer em um indivíduo que necessita do mesmo
CL2018000872A1 (es) Métodos de preservar la actividad biológica de los ácidos ribonucleicos.
AR115486A1 (es) Nucleasas guiadas por arn y sus fragmentos activos y variantes y métodos de uso
CL2019000920A1 (es) Métodos de preservar la actividad biológica de los ácidos ribonucleicos.